Bridge Biotherapeutics is a company that focuses on the development of novel drug candidates for areas with unmet medical needs. Their pipeline includes BBT-877 for idiopathic pulmonary fibrosis, BBT-401 for ulcerative colitis, and BBT-176 for non-small cell lung cancer. They are committed to developing high-quality therapeutics for patients worldwide through open innovation.
Bridge Biotherapeutics
Category:
Venture
Main Business Area
Bridge Biotherapeutics is a company that focuses on the development of novel drug candidates for areas with unmet medical needs. Their pipeline includes BBT-877 for idiopathic pulmonary fibrosis, BBT-401 for ulcerative colitis, and BBT-176 for non-small cell lung cancer. They are committed to developing high-quality therapeutics for patients worldwide through open innovation.
| Contact Details | Suite 303, C’s Tower, 58, Pangyo-ro 255 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 |
|---|
